1. Armaly MF. Inheritance of dexamethasone hypertension and glaucoma. Archives of ophthalmology. 1967;77(6):747-51. Epub 1967/06/01.
  2. Levene R, Wigdor A, Edelstein A, Baum J. Topical corticosteroid in normal patients and glaucoma suspects. Archives of ophthalmology. 1967;77(5):593-7. Epub 1967/05/01.
  3. Rohen JW, Linner E, Witmer R. Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma. Experimental eye research. 1973;17(1):19-31. Epub 1973/10/10.
  4. Clark AF, Wilson K, McCartney MD, Miggans ST, Kunkle M, Howe W. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Investigative ophthalmology & visual science. 1994;35(1):281-94. Epub 1994/01/01.
  5. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. The British journal of ophthalmology. 2003;87(1):24-7. Epub 2002/12/19.
  6. Rhee DJ, Peck RE, Belmont J, Martidis A, Liu M, Chang J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. The British journal of ophthalmology. 2006;90(8):999-1003. Epub 2006/04/07.
  7. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Archives of ophthalmology. 2004;122(3):336-40. Epub 2004/03/10.
  8. Haller JA, Bandello F, Belfort R, Jr., Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453-60. Epub 2011/07/19.
  9. Pearson PA, Comstock TL, Ip M, Callanan D, Morse LS, Ashton P, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011;118(8):1580-7. Epub 2011/08/05.
  10. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125-32. Epub 2012/06/26.
  11. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626-35 e2. Epub 2011/04/05.


2nd Edition - October 2013